Disruption of Type I Interferon Induction by a KSHV Homologue of IPS-1

Information

  • Research Project
  • 10258718
  • ApplicationId
    10258718
  • Core Project Number
    R21CA261297
  • Full Project Number
    1R21CA261297-01
  • Serial Number
    261297
  • FOA Number
    PA-20-195
  • Sub Project Id
  • Project Start Date
    4/15/2021 - 3 years ago
  • Project End Date
    3/31/2023 - a year ago
  • Program Officer Name
    READ-CONNOLE, ELIZABETH LEE
  • Budget Start Date
    4/15/2021 - 3 years ago
  • Budget End Date
    3/31/2023 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    4/14/2021 - 3 years ago

Disruption of Type I Interferon Induction by a KSHV Homologue of IPS-1

Project Abstract Herpes infections represent one of the most common viral infections that exists in the world. These viruses can be subclinical or as in the case of Kaposi?s Sarcoma Associated Herpesvirus (KSHV) they can lead to dangerous diseases such as cancer. KSHV is well known in AIDS patients to cause Kaposi?s Sarcoma (KS) and several other lymphoproliferartive diseases. Type I Interferon is well known to be the body?s natural anti- viral system and almost all viruses that cause infection in humans have devolved ways to block or use this system to enhance their replication in the host. We have found a novel ORF within the genome of KSHV that seems to be a viral homologue of the IPS1 protein, a critical adaptor of the Type I Interferon induction pathway. This protein is highly expressed during KSHV lytic viral replication. The overall goal of this application is to determine how KSHV uses this novel viral protein to manipulate the innate immune system that should normally limit KSHV replication. In the first specific aim, we will focus on determining how KSHV uses this gene to disrupt IFN as well as replicate efficiently. In the second aim, we plan to determine the importance of this novel gene by the construction and characterization of a KSHV deficient in this viral homologue of IPS1. The long-term goal of this project is to determine how KSHV immune modulation occurs in the goal of blocking this manipulation and limiting KSHV replication.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R21
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
    257125
  • Indirect Cost Amount
    90087
  • Total Cost
    347212
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
    SCHOOLS OF PHARMACY
  • Funding ICs
    NCI:347212\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HCAC
  • Study Section Name
    HIV Coinfections and HIV Associated Cancers Study Section
  • Organization Name
    WESTERN UNIVERSITY OF HEALTH SCIENCES
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    093373694
  • Organization City
    POMONA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    917661854
  • Organization District
    UNITED STATES